| |
Company
Roster
|
|
Total
Insiders : |
14 |
|
|
|
Total
Direct Shares :
|
678,280 |
|
|
Total
Indirect Shares :
|
3,961,957 |
| |
%
Held by Insiders:
|
2.61% |
|
|
| |
| Filer's Name |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
  Szalay Aladar |
|
2023-09-19 |
0 |
2024-05-15 |
3,953,581 |
| Zhang Qian |
Associate VP, Research |
2023-02-17 |
139,333 |
2023-02-17 |
200 |
| Samuelson Doug |
Chief Financial Officer |
2023-08-18 |
2,303 |
2023-02-17 |
0 |
| Woodward Gabe |
Director |
2023-02-17 |
4,186 |
2023-02-17 |
8,176 |
| Mirabelli Mary |
Director |
2023-09-11 |
4,460 |
2023-02-17 |
0 |
| Smither John W |
Director |
2023-09-13 |
6,920 |
2023-09-11 |
0 |
| Thomas John |
Director |
2023-12-13 |
463,460 |
2023-01-30 |
0 |
| Tyree James L |
Director |
2023-12-13 |
3,460 |
2023-02-17 |
0 |
| Ryder Sean |
General Counsel |
2023-09-20 |
572 |
2023-02-17 |
0 |
| Jewett Caroline |
Head of Quality |
2023-09-11 |
21,135 |
|
0 |
| Smalling Ralph |
Head of Regulatory |
2023-09-11 |
12,065 |
|
0 |
| Zindrick Thomas |
President and CEO, Director |
2023-08-18 |
14,651 |
2023-02-27 |
0 |
| Yu Tony |
VP, Clinical Trial Operations |
2023-12-15 |
0 |
|
0 |
| Cappello Joseph |
VP, Pharmaceutical Development |
2023-08-18 |
5,735 |
2023-02-17 |
0 |
|
1.98 (43.04%) 
